Drug firm Alkem Laboratories on Tuesday said it has entered an asset purchase agreement with AbbVie Inc, USA, for acquisition of certain assets related to active pharmaceutical ingredient, Dronabinol, for over USD 10 million approximately Rs 71 crore).
The assets related to Dronabinol include domain names and trademarks pertaining to 'Marinol', New Drug Application (NDA) registration with US Food and Drug Administration (USFDA) for Marinol, logos, patents designs, know how, technical and manufacturing instructions, inventory, manufacturing equipment and such items, Alkem Laboratories said in a filing to BSE.
The cost of acquisition is cash consideration of USD 10 million plus suitable working capital adjustments on closing, it added.
The objects of the acquisition is, "The company shall own the NDA and associated assets and will use these to commercially exploit both branded and generic sales in the US," Alkem Laboratories said.
Shares of Alkem Laboratories were trading at Rs 2,025.45 per scrip on BSE, up 1.81 per cent from their previous close.
Disclaimer: No Business Standard Journalist was involved in creation of this content
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app